A Phase 2 Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2017
At a glance
- Drugs SU 014813 (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Pfizer
- 01 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 May 2009 Planned end date changed from 1 Nov 2008 to 1 Nov 2009 as reported by ClinicalTrials.gov.
- 02 Aug 2008 Status changed from recruiting to active, no longer recruiting.